MaaT Pharma SA

DB:4RD Stock Report

Market Cap: €106.6m

MaaT Pharma Future Growth

Future criteria checks 2/6

MaaT Pharma is forecast to grow earnings and revenue by 0.6% and 59.7% per annum respectively while EPS is expected to grow by 2.6% per annum.

Key information

0.6%

Earnings growth rate

2.6%

EPS growth rate

Biotechs earnings growth42.4%
Revenue growth rate59.7%
Future return on equityn/a
Analyst coverage

Low

Last updated07 Nov 2024

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:4RD - Analysts future estimates and past financials data (EUR Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202613-22-2-22
12/31/20254-32-21-153
12/31/20244-29-34-283
6/30/20243-24-19-18N/A
3/31/20242-22-19-18N/A
12/31/20232-20-20-19N/A
9/30/20232-17-20-19N/A
6/30/20232-15-20-19N/A
3/31/20232-14-16-16N/A
12/31/20221-14-13-13N/A
9/30/20221-13-12-12N/A
6/30/20221-12-11-11N/A
3/31/20221-11-10-9N/A
12/31/20211-9-8-8N/A
9/30/20210-8-8-8N/A
6/30/2021-1-7-9-8N/A
3/31/20210-6-7-7N/A
12/31/2020N/A-5-6-6N/A
12/31/20190-5N/AN/AN/A
12/31/20181-4-4-4N/A
12/31/20170-4N/AN/AN/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 4RD is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 4RD is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 4RD is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 4RD's revenue (59.7% per year) is forecast to grow faster than the German market (5.6% per year).

High Growth Revenue: 4RD's revenue (59.7% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 4RD's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y